ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cerecor gets rare disease firm Ichorion

by Lisa M. Jarvis
September 28, 2018 | APPEARED IN VOLUME 96, ISSUE 39

 

Cerecor will acquire rare-disease-drug-focused Ichorion Therapeutics in an all-stock deal worth $26.6 million. Ichorion is developing treatments for rare metabolic disorders, including several substrate replacement therapies. In addition to expanding its pipeline in neurology and pediatric orphan diseases, Cerecor says, the deal adds two drug candidates eligible for rare pediatric disease priority review vouchers, transferable assets that shorten FDA’s review time.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment